A new conceptual model provides a framework for early health technology assessment of tissue-engineered heart valves to guide development and reimbursement decisions.
We developed a CM that will serve as foundation of a decision-analytic model that can estimate the potential cost-effectiveness of TEHV in early development stages. This supports developers in deciding about further development of TEHV and identifies promising interventions that may result in faster take-up in clinical practice by clinicians and reimbursement by payers.
Huygens et al. (Sat,) studied this question.